Relyea Zuckerberg Hanson LLC bought a new position in shares of Pfizer Inc. (NYSE:PFE) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm bought 7,037 shares of the biopharmaceutical company’s stock, valued at approximately $276,000.
A number of other large investors also recently made changes to their positions in the stock. Nuveen Asset Management LLC lifted its position in shares of Pfizer by 2,240.5% in the 2nd quarter. Nuveen Asset Management LLC now owns 36,086,254 shares of the biopharmaceutical company’s stock worth $1,563,256,000 after purchasing an additional 34,544,423 shares during the period. Natixis bought a new position in Pfizer during the second quarter worth $258,466,000. DNB Asset Management AS lifted its holdings in Pfizer by 241.0% in the third quarter. DNB Asset Management AS now owns 3,734,044 shares of the biopharmaceutical company’s stock valued at $134,164,000 after buying an additional 2,638,873 shares during the period. Eagle Asset Management Inc. lifted its holdings in Pfizer by 84.9% in the third quarter. Eagle Asset Management Inc. now owns 3,816,935 shares of the biopharmaceutical company’s stock valued at $137,142,000 after buying an additional 1,752,551 shares during the period. Finally, California Public Employees Retirement System boosted its position in Pfizer by 5.3% during the second quarter. California Public Employees Retirement System now owns 23,186,244 shares of the biopharmaceutical company’s stock valued at $1,004,428,000 after acquiring an additional 1,159,857 shares during the last quarter. 70.21% of the stock is owned by institutional investors and hedge funds.
Shares of PFE opened at $40.67 on Thursday. The business’s fifty day moving average is $38.90 and its 200 day moving average is $38.18. Pfizer Inc. has a 12-month low of $33.97 and a 12-month high of $44.56. The company has a quick ratio of 0.68, a current ratio of 0.90 and a debt-to-equity ratio of 0.55. The stock has a market cap of $218.54 billion, a P/E ratio of 13.56, a P/E/G ratio of 4.18 and a beta of 0.65.
Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, October 29th. The biopharmaceutical company reported $0.75 EPS for the quarter, beating the Zacks’ consensus estimate of $0.62 by $0.13. Pfizer had a net margin of 30.57% and a return on equity of 28.10%. The business had revenue of $12.68 billion during the quarter, compared to analyst estimates of $12.37 billion. During the same quarter in the previous year, the business posted $0.78 EPS. Pfizer’s quarterly revenue was down 4.6% on a year-over-year basis. On average, analysts expect that Pfizer Inc. will post 2.97 EPS for the current year.
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 6th. Stockholders of record on Friday, January 31st will be issued a dividend of $0.38 per share. This is a boost from Pfizer’s previous quarterly dividend of $0.36. This represents a $1.52 dividend on an annualized basis and a dividend yield of 3.74%. The ex-dividend date is Thursday, January 30th. Pfizer’s dividend payout ratio (DPR) is currently 48.00%.
A number of analysts have weighed in on PFE shares. ValuEngine upgraded Pfizer from a “sell” rating to a “hold” rating in a report on Wednesday, October 2nd. JPMorgan Chase & Co. restated a “neutral” rating on shares of Pfizer in a research report on Tuesday, October 29th. Royal Bank of Canada began coverage on Pfizer in a research note on Monday, January 6th. They set an “outperform” rating and a $46.00 target price for the company. Zacks Investment Research upgraded Pfizer from a “sell” rating to a “strong-buy” rating and set a $38.00 target price for the company in a report on Tuesday, October 1st. Finally, Credit Suisse Group reissued a “hold” rating and issued a $41.30 price target on shares of Pfizer in a research note on Wednesday, November 6th. Nine research analysts have rated the stock with a hold rating, four have issued a buy rating and one has issued a strong buy rating to the stock. Pfizer currently has an average rating of “Hold” and a consensus target price of $43.41.
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.
Featured Article: Cost of Goods Sold (COGS)
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.